Voglibose & Metformin Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: (Voglibose 0.2/0.3 mg) + (Metformin 500/850 mg)

Reference Brands: Voglimet, Voglinorm-M, Volibo-M, Vogli-Met(India/Japan)

Category: Diabetes

Metformin reduces hepatic glucose production and increases insulin sensitivity, while Voglibose delays carbohydrate absorption in the intestine by inhibiting α-glucosidase. Together, they effectively control fasting and postprandial blood glucose. This synergistic action improves glycemic control in Type 2 Diabetes, especially in patients with high post-meal glucose spikes. Voglibose & Metformin Tablets is available in Tablets and strengths such as (Voglibose 0.2/0.3 mg) + (Metformin 500/850 mg). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Voglibose & Metformin Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Voglibose & Metformin Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Voglibose + Metformin combination tablets (0.2/0.3 mg Voglibose with 500/850 mg Metformin) are not approved by the FDA (USA) or EMA (EU) for marketing. Voglibose lacks regulatory approval in both regions due to limited clinical data per Western standards. However, this fixed-dose combination is widely approved and marketed in India, Japan, and other parts of Asia for managing Type 2 Diabetes Mellitus, particularly for postprandial hyperglycemia. Brands like Voglimet, Voglinorm-M, and Volibo-M are common. For sourcing, global B2B buyers can access compliant manufacturers through platforms like Pharmatradz.com.